Abstract Number: 1703 • 2016 ACR/ARHP Annual Meeting
Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial
Background/Purpose: ACTIVE is the first apremilast (APR) trial that evaluated time to onset of efficacy beginning at Wk 2 in psoriatic arthritis (PsA) patients (pts)…Abstract Number: 1704 • 2016 ACR/ARHP Annual Meeting
Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Background/Purpose: Pooled safety data from the psoriasis (PsO) and psoriatic arthritis (PsA) clinical trial programs of secukinumab (SEC), through approximately 1 year, have been reported…Abstract Number: 1705 • 2016 ACR/ARHP Annual Meeting
The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
Background/Purpose: While rheumatoid arthritis (RA) has been linked to an increased incidence of osteoporosis (OP) and fracture, few studies have examined the risk of fracture…Abstract Number: 1706 • 2016 ACR/ARHP Annual Meeting
Quality of Life at Baseline in Early Psoriatic Arthritis Related to Disease Domains
Background/Purpose: Psoriatic arthritis (PsA) is a multifaceted disease. Affecting joints, skin, entheses and dactylitis, its impact on health-related quality-of-life (HRQoL) could be substantial. Up to…Abstract Number: 1707 • 2016 ACR/ARHP Annual Meeting
Ustekinumab and the Comparative Risk for Acute Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis
Background/Purpose: Ustekinumab (UST), an anti IL12/IL23 monoclonal antibody, is a relatively new biologic used for the treatment of psoriasis (PSO) and psoriatic arthritis (PSA). Its…Abstract Number: 1708 • 2016 ACR/ARHP Annual Meeting
Cutaneous Microbiota Features Distinguish Psoriasis from Psoriatic Arthritis
Background/Purpose: Psoriasis (PsO) is a chronic immune-mediated skin condition affecting ~3% of adults worldwide. Up to a third of PsO patients go on to…Abstract Number: 1709 • 2016 ACR/ARHP Annual Meeting
Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis
Background/Purpose: CHS-0214 is a proposed biosimilar of etanercept, a fusion protein inhibiting tumor necrosis factor. This Phase III multi-center study compared the efficacy and safety…Abstract Number: 1710 • 2016 ACR/ARHP Annual Meeting
Musculoskeletal Symptoms Preceding the Diagnosis of Psoriatic Arthritis – a Qualitative Exploration of the Patient Journey
Background/Purpose: Given the difficulties non-rheumatologists experience to early refer psoriasis patients at risk for Psoriatic Arthritis (PsA) we aim to explore patients experience of musculoskeletal…Abstract Number: 1711 • 2016 ACR/ARHP Annual Meeting
Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials
Background/Purpose: Of the multiple manifestations of psoriatic arthritis (PsA), enthesitis and dactylitis are hallmark features that affect many patients (pts), can lead to pain and…Abstract Number: 1712 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Physical Functioning and Work for People with Psoriatic Arthritis: Results from a Large Real-World Study in 16 Countries
Background/Purpose: <3); employment status and the four WPAI components (work time missed, impairment while working, overall work impairment, and activity impairment) were described by HAQ-DI…Abstract Number: 1713 • 2016 ACR/ARHP Annual Meeting
Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune activity in psoriatic arthritis (PsA) patients. PALACE 1 (NCT01172938), 2 (NCT01212757), and 3…Abstract Number: 1714 • 2016 ACR/ARHP Annual Meeting
Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (PsO) are at increased risk of cardiovascular diseases (CVD) and the risk is higher in patients with…Abstract Number: 1715 • 2016 ACR/ARHP Annual Meeting
ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…Abstract Number: 1716 • 2016 ACR/ARHP Annual Meeting
Higher Frequency and Severity of Coronary Plaques on Coronary CT Angiography in Psoriatic Arthritis Patients without Symptoms of Coronary Artery Disease Compared to Controls
Background/Purpose: Patients with psoriasis (PsO) and psoriatic arthritis (PsA) have an increased prevalence of cardiovascular (CV) risk factors, metabolic syndrome (Metsy), and higher risk…Abstract Number: 1717 • 2016 ACR/ARHP Annual Meeting
Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors
Background/Purpose: Axial involvement in psoriatic arthritis (PsA) is a controversial issue. Lack of unanimity in the definition has led to a wide range of…
ACR Meeting Abstracts